Replies to post #1383 on BioCurex, Inc.(fka BOCX)

[good-pal]

"we are dealing with the NASD on the matter"....bocxman you know that it dos not take that long (18 months) unless there is somthing REALLY WRONG with bocx.

"the reason we were delisted to the pinks is because the SEC halt triggered the arcane NASD rule that companies go to pink sheets if there is no bid in the stock for 10 days. the SEC never decided to list BOCX...they simply halted the stock to do discovery"

lol bocxman...the reason we were halted and then delisted is because the sec is questioning bocx claims regarding:

1-a study confirming the effectiveness of its primary product

2-approval of its main product by the Food and Drug Administration.

bocxman...this may refresh your memory:

For Immediate Release
April 10th. 2004

BioCurex Responds To Trading Suspension By The SEC.

On April 8, 2004 the Securities and Exchange Commission temporarily suspended trading in the common stock of Biocurex Inc. due to "questions regarding the accuracy of assertions by Biocurex and others, in press releases and e-mails to investors concerning, among other things, (1) a study confirming the effectiveness of its primary product and (2) approval of its main product by the Food and Drug Administration".

The company wishes to communicate to its shareholders the following:

1)Biocurex has notified the SEC that it is eager to answer any questions the SEC may have regarding these issues and is presently awaiting a response from the SEC on this matter.
2)Biocurex is not responsible for the unauthorized circulation of corporate material "by others", nor any material that could be construed as misleading to investors or outright erroneous in its content.
3)The Food and Drug Administration has classified Biocurex's Histo-RECAFTM as a Class I device under Regulation Number 864.1850, Code HZJ owned by BioCurex (FDA number 9046509). Thus, the product is available as a "Staining test for AFP receptors (a.k.a. RECAF) in tissues" for sale to pathology laboratories across the USA. The pertinent documents from the FDA can be found by doing a search for Biocurex at http://google.fda.gov.
4)Biocurex firmly stands by the results announced in its April 5, 2004 press release and by its RECAF technology in general.
BioCurex Inc. wishes to thank its shareholders for their patience and for the many expressions of support we have received in the past few days. The Company also wishes to assure its investors that it will continue to work towards the successful introduction of its technology.
To read more about the state of the company, please visit the News section in our web site (www.biocurex.com).